European Pharmaceutical Review

JANUARY 3, 2024

Korserdu ® (elacestrant) is the first treatment indicated for ER+, HER2- advanced or metastatic breast cancer tumours with ESR1 mutations. Data supporting MHRA’s authorisation of Korserdu (elacestrant) Data from the Phase III EMERALD trial was published in the ASCO Journal of Clinical Oncology. months versus 1.9 months versus 1.9

Medicine 105

Medicine Marketing Patients Healthcare 105

Pharmaceutical Technology

JANUARY 13, 2023

Health Canada has granted approval to Enhertu (trastuzumab deruxtecan) to treat unresectable or metastatic HER2-low (IHC 1+ or IHC 2+/ISH-) breast cancer. Enhertu’s safety profile was consistent with the previous clinical trials.

Engineering 128

Engineering Safety Patients Medicine 128

Pharmaceutical Technology

FEBRUARY 8, 2024

DX-126262 is under clinical development by Hangzhou DAC Biotech and currently in Phase I for Breast Cancer.

98

98

MedCity News

AUGUST 15, 2022

Gilead Sciences said it has statistically significant and clinically meaningful data from a pivotal test of its cancer drug, Trodelvy, in the most common type of breast cancer.

FDA 98

FDA Patients Biopharma Pharma 98

Pharmaceutical Technology

APRIL 17, 2024

B-Vaxx is under clinical development by Imugene and currently in Phase II for Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer (HER2+ Breast Cancer).

40

40

European Pharmaceutical Review

OCTOBER 26, 2023

In August 2023, Biswajit Podder, PhD, Oncology and Hematology Analyst at GlobalData shared that HER2-positive breast cancer “seems to be a major focus” in ADC drug development. Clinically meaningful PFS benefit was seen in patients with non-squamous tumours. Can you summarise the key new data from the TROPION-programme?

Patients 98

Patients Pharmaceutical Safety Marketing 98

European Pharmaceutical Review

JULY 24, 2023

A novel breast cancer treatment The anti-cancer therapeutic is indicated for postmenopausal women, and adult men, with these clinical biomarkers. The post Will ESR1-mutated breast cancer treatment gain approval? ESR1 mutations are acquired mutations that develop due to endocrine therapy exposure.

Medicine 86

Medicine Patients Pharmaceutical 86

Medgadget

AUGUST 22, 2023

Researchers at MIT have developed a wearable ultrasound system that is intended to allow women at high risk of breast cancer to perform an ultrasound scan on themselves at home, and may also let patients with early-stage malignancy or suspicious lesions to monitor how they are progressing. Early detection is crucial in cancer.

Patients 76

Patients 76

Pharmacy Times

JUNE 30, 2022

Moore, PharmD, BCOP, CPP, and Susan Faye Dent, MD, FRCPC, FICQS, emphasize the critical role of the pharmacist in achieving clinical endpoints in advanced-stage breast cancer.

26

26

Pharmaceutical Technology

APRIL 19, 2024

SGN-1 is under clinical development by Guangzhou Huajin Pharmaceutical Technology and currently in Phase II for Breast Cancer.

Pharmaceutical 40

Pharmaceutical 40

pharmaphorum

OCTOBER 17, 2022

Bayer has added another clinical trial to its extensive phase 3 programme for oral neurokinin antagonist elinzanetant, hoping to show that it can treat vasomotor symptoms (VMS) in breast cancer patients. There are around 2.3

Patients 104

Patients Medical FDA Leads 104

Pharmaceutical Technology

APRIL 17, 2024

SLATE-001 is under clinical development by Gritstone Bio and currently in Phase I for Metastatic Breast Cancer.

40

40

Pharmaceutical Technology

AUGUST 8, 2022

AstraZeneca and Daiichi Sankyo ’s Enhertu (trastuzumab deruxtecan) has received expanded approval from the US Food and Drug Administration (FDA) to treat adults with unresectable or metastatic HER2-low (IHC 1+ or IHC 2+/ISH-) breast cancer. In these subjects, the median progression-free survival (PFS) following Enhertu treatment was 9.9

Food and Drug Administration 105

Food and Drug Administration FDA Safety Food 105

Pharmaceutical Technology

FEBRUARY 19, 2024

AC-0682 is under clinical development by Accutar Biotechnology and currently in Phase I for Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer).

40

40

Pharmaceutical Technology

FEBRUARY 7, 2024

Enfortumab vedotin is under clinical development by Astellas Pharma and currently in Phase II for Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer).

Pharma 40

Pharma 40

Pharmaceutical Technology

FEBRUARY 7, 2024

Trastuzumab biosimilar is under clinical development by Qilu Pharmaceutical and currently in Phase III for Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer (HER2+ Breast Cancer).

Pharmaceutical 40

Pharmaceutical 40

PharmaTimes

MARCH 14, 2023

The clinical trial also involves paclitaxel in the treatment of metastatic breast cancer

105

105

European Pharmaceutical Review

JANUARY 26, 2023

Enhertu (trastuzumab deruxtecan) has been approved in the European Union (EU) for adults with unresectable or metastatic HER2-low (IHC 1+ or IHC 2+/ISH-) breast cancer. The antibody drug conjugate (ADC) is the first HER2-directed therapy for HER2-low metastatic breast cancer.

Safety 83

Safety Medicine Patients Pharmaceutical 83

World of DTC Marketing

JANUARY 4, 2022

after they were diagnosed with metastatic colon cancer. According to the study “financial hardship or “financial toxicity” is an increasingly recognized consequence of cancer treatment that results from high out-of-pocket medical costs (e.g., National costs for cancer care were estimated to be $190.2

Insurance 273

Insurance Transportation Medical Prescription 273

Pharmaceutical Technology

JANUARY 27, 2023

The European Union (EU) has granted approval for Daiichi Sankyo and AstraZeneca ’s Enhertu (trastuzumab deruxtecan) as monotherapy to treat unresectable or metastatic HER2 low (IHC 1+ or IHC 2+/ISH-) breast cancer adult patients.

Engineering 94

Engineering Safety Medicine Patients 94

European Pharmaceutical Review

OCTOBER 6, 2022

The US Food and Drug Administration (FDA) has approved Roche’s PATHWAY anti-HER2/neu (4B5) Rabbit Monoclonal Primary Antibody (PATHWAY anti-HER2 (4B5) test), which identifies low HER2 expression in metastatic breast cancer. HER2 is a receptor protein that helps cancer cells grow quickly. Every year 2.3

Food and Drug Administration 81

Food and Drug Administration Patients Safety Food 81

Pharmaceutical Technology

DECEMBER 26, 2023

Sacituzumab tirumotecan is under clinical development by Merck and currently in Phase II for Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer).

40

40

pharmaphorum

DECEMBER 12, 2022

The San Antonio Breast Cancer Symposium (SABCS) has highlighted some of the most promising clinical research being undertaken by drugmakers in the category, with AstraZeneca leading the charge with a trio of major trial readouts. after four years’ follow-up, an improvement on the 2.8% seen at two years.

Pharma 88

Pharma Physicians Patients Leads 88

Pharmaceutical Technology

DECEMBER 20, 2023

Nivolumab is under clinical development by Bristol-Myers Squibb and currently in Phase III for Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer).

40

40

Pharmaceutical Technology

DECEMBER 20, 2023

Afuresertib hydrochloride is under clinical development by Laekna Therapeutics Shanghai and currently in Phase III for Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer).

40

40

Pharmaceutical Commerce

DECEMBER 1, 2023

Ongoing clinical trials are evaluating zotatifin (eFT226) plus Faslodex (fulvestrant) and Verzenio (abemaciclib) for the treatment of ER–positive, HER2-negative advanced or metastatic breast cancer.

FDA 52

FDA 52

Pharmaceutical Technology

DECEMBER 6, 2023

DB-1310 is under clinical development by Duality Biologics (Shanghai) and currently in Phase II for Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer (HER2+ Breast Cancer).

40

40

Pharmaceutical Technology

DECEMBER 4, 2023

BMS-986360 is under clinical development by Bristol-Myers Squibb and currently in Phase I for Triple-Negative Breast Cancer (TNBC).

52

52

World of DTC Marketing

OCTOBER 6, 2020

WHAT’S THIS ABOUT THEN : Researchers are rushing to launch clinical trials of experimental vaccines against the coronavirus, and treatments for COVID-19. We are now seeing impacts on clinical-trial continuity in all the regions where we conduct clinical studies.”.

Patients 180

Patients Physicians Networking Pharmaceutical 180

pharmaphorum

JULY 14, 2022

Cost-effectiveness watchdog NICE has recommended routine NHS use of two new therapies for women with advanced breast cancer – Gilead’s Trodelvy and Novartis’ Piqray – in England. .

Side effects 84

Side effects Medicine Patients Government 84

Pharmaceutical Technology

JUNE 28, 2022

The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended granting approval for AstraZeneca and Merck’s (MSD outside the US and Canada) Lynparza (olaparib) as adjuvant therapy for high-risk early breast cancer patients.

Safety 64

Safety Medicine Patients Medical 64

Pharmaceutical Technology

NOVEMBER 18, 2023

BB-1701 is under clinical development by Bliss Biopharmaceutical (Hangzhou) and currently in Phase II for Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer (HER2+ Breast Cancer).

40

40

Pharmaceutical Technology

JUNE 2, 2023

Kicking off this year’s American Society of Clinical Oncology’s (ASCO) conference, Novartis has released data supporting the use of its CDK4/6 inhibitor Kisqali (ribociclib) as an adjuvant treatment for a group of early-stage breast cancer patients.

Food and Drug Administration 52

Food and Drug Administration Healthcare Provider Patients Food 52

Legacy MEDSearch

NOVEMBER 1, 2023

Paige, a global leader in end-to-end digital pathology solutions and clinical AI applications that assist in diagnosing cancer, announced today that the U.S Paige Lymph Node detects the presence of breast cancer metastases with near-perfect sensitivity 3. Klimstra, M.D., Founder and Chief Medical Officer at Paige.

FDA 52

FDA Food and Drug Administration Recruitment Management 52

Pharmaceutical Technology

DECEMBER 22, 2023

Atamparib is under clinical development by Ribon Therapeutics and currently in Phase II for Breast Cancer.

52

52

European Pharmaceutical Review

MARCH 6, 2024

Keren Haruvi, President Sandoz North America highlighted that denosumab is a medicine that can address primary and secondary bone loss, such as osteoporosis, as well as cancer-related skeletal events. Wyost Similarly, Wyost 120 mg/1.7 mL (70 mg/mL) injection is a human monoclonal antibody designed to bind to the RANKL protein.

Food and Drug Administration 93

Food and Drug Administration Medicine FDA Food 93

MedCity News

JANUARY 30, 2024

Even just a year ago, we couldn’t fathom a cure for cancer. Cancer treatment is one area that could benefit significantly from AI, as it can aid in early detection, precise diagnosis, and personalized treatment plans. AI algorithms can analyze medical images and identify any abnormalities that may indicate cancer. Now, we can.

Side effects 127

Side effects Ethics Medical Patients 127